Combination of Crizotinib and Osimertinib or Erlotinib Might Overcome MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutated Adenocarcinoma.
In: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, Jg. 13 (2018-11-01), Heft 11, S. e232-e234
report
Zugriff:
Titel: |
Combination of Crizotinib and Osimertinib or Erlotinib Might Overcome MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutated Adenocarcinoma.
|
---|---|
Autor/in / Beteiligte Person: | Giroux-Leprieur, E ; Dumenil, C ; Chinet, T |
Zeitschrift: | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, Jg. 13 (2018-11-01), Heft 11, S. e232-e234 |
Veröffentlichung: | 2016- : New York, NY : Elsevier ; <i>Original Publication</i>: Hagerstown, MD : Lippincott Williams & Wilkins, c2006-, 2018 |
Medientyp: | report |
ISSN: | 1556-1380 (electronic) |
DOI: | 10.1016/j.jtho.2018.07.012 |
Schlagwort: |
|
Sonstiges: |
|